Detalhe da pesquisa
1.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet
; 393(10167): 143-155, 2019 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30420123
2.
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
AIDS
; 36(1): 39-48, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534138
3.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr
; 83(3): 310-318, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31834000
4.
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
AIDS
; 33(9): 1455-1465, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30932951
5.
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
J Acquir Immune Defic Syndr
; 75(2): 211-218, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28282300